{"id":313,"date":"2026-09-23T06:00:18","date_gmt":"2026-09-23T06:00:18","guid":{"rendered":"https:\/\/noimfine.com\/sph06\/?p=313"},"modified":"2026-09-23T06:02:41","modified_gmt":"2026-09-23T06:02:41","slug":"xocova-fda-approves-first-oral-post-exposure-prophylaxis-to-help-prevent-covid-19-in-adults-and-adolescents-12-and-older","status":"publish","type":"post","link":"https:\/\/noimfine.com\/sph06\/2026\/09\/23\/xocova-fda-approves-first-oral-post-exposure-prophylaxis-to-help-prevent-covid-19-in-adults-and-adolescents-12-and-older\/","title":{"rendered":"Xocova: FDA Approves First Oral Post-Exposure Prophylaxis to Help Prevent COVID-19 in Adults and Adolescents 12 and Older"},"content":{"rendered":"
\n

<\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
Xocova (ensitrelvir)<\/a> is a prescription antiviral medicine you take by mouth to lower your chance of getting COVID-19 after you have been in close contact with someone who has the virus. It is approved for adults and for adolescents 12 and older. This medicine is the first oral medication approved in the U.S. for prevention after exposure.Xocova targets the coronavirus that causes COVID-19 (SARS\u2011CoV\u20112). It blocks the virus\u2019s main protease (Mpro), an enzyme the virus needs to make copies of itself. By blocking this process, Xocova makes it harder for the virus to multiply in your body after exposure.<\/p>\n

COVID-19 continues to spread easily, especially within households. If you live with someone who is sick, nearly half of close contacts may become infected. Research has linked the virus to an increased risk of new or worsening heart, lung, kidney, and neurological conditions in the months following illness. Older adults remain especially vulnerable to severe disease, particularly in shared living environments such as nursing homes and long-term care facilities.<\/p>\n

From fall through late spring in the U.S., millions of new cases were estimated, leading to clinic visits, hospital stays, and deaths. Having an at\u2011home preventive treatment that you can start soon after exposure may help reduce the risk, especially for people in the same household who have someone with COVID.<\/p>\n<\/section>\n

\n

Why Was It Approved?<\/h2>\n

FDA approval was supported by a study of 2,387 people exposed to a symptomatic case in their household. Participants were 12 or older, had no symptoms when they enrolled, and had a negative local screening test. Nearly all had some level of immunity from prior infection, vaccination, or both. Treatment began within 72 hours after the sick household member first developed symptoms.<\/p>\n

In the primary analysis of 2,041 participants who tested negative in lab results for SARS-CoV-2 at the start of the study, Xocova reduced the risk of developing symptomatic COVID by 67% through Day 10 compared with a placebo.<\/p>\n

The benefit looked consistent across groups and did not depend on vaccination status or past infection.<\/p>\n

Xocova was generally well-tolerated in the study. The most common side effects were headache, diarrhea, and cough. Other reported side effects included high blood pressure and high blood levels of potassium.<\/p>\n<\/section>\n<\/div>\n

\n
\n

What Do I Need to Know?<\/h2>\n

Start Xocova as soon as you can, within 72 hours after close contact with someone who has COVID. Take Xocova once daily for five days. Take three tablets together on Day 1 (375 milligrams total), then one tablet daily on days 2 through 5 (125 milligrams each day). You can take it with or without food. Take each dose at about the same time. If you miss a dose, take it later that same day and resume your usual schedule the next day.<\/p>\n<\/section>\n

Your health care provider will check if you are pregnant before you start treatment. If you could become pregnant, use effective birth control while taking Xocova and for two weeks after the last dose. Do not breastfeed during treatment and for at least two weeks after the final dose.Do not use Xocova if you have had a serious allergy to it. Get medical help right away if you develop swelling, trouble breathing, a rash, or hives.<\/p>\n

Some medicines should not be taken with Xocova because of dangerous interactions, including drugs that mainly rely on the liver enzyme CYP3A or strong CYP3A inducers. Xocova strongly blocks CYP3A and the transport proteins P\u2011glycoprotein (P\u2011gp) and breast cancer resistance protein (BCRP). This can sharply raise levels of many medicines. Review all prescription and over\u2011the\u2011counter products and supplements with your health care provider before starting. Examples of medicines you must not take with Xocova include carbamazepine, enzalutamide, lurasidone, quinidine, rifampin, simvastatin, St. John\u2019s wort, and triazolam.<\/p>\n

Xocova helps prevent symptomatic COVID after a known exposure. It is not approved to treat COVID in the U.S.<\/p>\n<\/section>\n<\/div>\n<\/div>\n

<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Xocova (ensitrelvir) is a prescription antiviral medicine you take by mouth to lower your chance of getting COVID-19 after you have been in close contact with someone who has the virus. It is approved for adults and for adolescents 12… <\/p>\n","protected":false},"author":2,"featured_media":315,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-spot"],"_links":{"self":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/comments?post=313"}],"version-history":[{"count":2,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/313\/revisions"}],"predecessor-version":[{"id":317,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/313\/revisions\/317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media\/315"}],"wp:attachment":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media?parent=313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/categories?post=313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/tags?post=313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}